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Combination of conjugated linoleic acid with fish oil prevents
age-associated bone marrow adiposity in C57Bl/6J mice
Ganesh V Halade1, Md M Rahman1, Paul J Williams, and Gabriel Fernandes
Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Texas
Health Science Center at San Antonio, 7703 Floyd Curl Drive, Texas 78229-3900, USA.

Abstract
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The inverse relationship between fat in bone marrow and bone mass in the skeleton of aging
subjects is well-known. However, there is no precise therapy for the treatment of bone marrow
adiposity. We investigated the ability of conjugated linoleic acid (CLA) and fish oil (FO), alone or
in combination, to modulate bone loss using 12 months old C57Bl/6J mice fed 10% corn oil (CO)
diet as control or supplemented with 0.5% CLA or 5% FO or 0.5% CLA+5% FO for 6 months.
We found, CLA fed mice exhibited reduced body weight, body fat mass (BFM), and enhanced
hind leg lean mass (HLLM) and bone mineral density (BMD) in different regions measured by
DXA; however, associated with fatty liver and increased insulin resistance; whereas, FO fed mice
exhibited enhanced BMD, improved insulin sensitivity, with no changes in BFM and HLLM.
Interestingly, CLA+FO fed mice exhibited reduced body weight, BFM, PPARγ and cathepsin K
expression in bone marrow with enhanced BMD and HLLM. Moreover, CLA+FO
supplementation reduced liver hypertrophy and improved insulin sensitivity with remarkable
attenuation of bone marrow adiposity, inflammation and oxidative stress in aging mice. Therefore,
CLA with FO combination might be a novel dietary supplement to reduce fat mass and improve
BMD.
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1. Introduction
An enhanced adipogenesis in the bone marrow (BM) is inversely correlated to trabecular
bone volume during aging and in patients with osteoporosis (1). Osteoporosis is a major
public health concern characterized by excessive skeletal fragility in the aging population.
The direct cost associated with obesity in the United States is ~$100 billion and for
osteoporosis, it has risen rapidly and reached ~17.5 billion dollars per year (2). Bone tissue
undergoes remodeling throughout life, balancing between bone resorption and bone
formation. Imbalances of bone remodeling can result in gross perturbations in skeletal
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structure and function, and potentially to morbidity and shortening of lifespan (3). Currently
there is no precise therapy to treat age-associated BM adiposity. Recently, there is an
extensive interest in the potential health benefits of dietary supplementation with conjugated
linoleic acid (CLA), including anti-carcinogenic and anti-tumorogenic effects (4), reduction
in the risk of atherosclerosis, hypertension, and diabetes, improvement in food efficiency,
promotion of energy metabolism, anti-osteoporotic and positive effect on immune function
(5). On the other hand, the beneficial effect of FO has been demonstrated in several human
diseases, including cardiovascular diseases (6), autoimmune inflammatory diseases,
rheumatoid arthritis, inflammatory bowel disease, osteoporosis (7,8), sepsis, vascular
compliance, blood pressure (9), diabetes (10) etc. In view of its beneficial effects, the FO
formulation OMACOR® (Currently marketed as LOVAZA®, by GSK Inc. USA) has been
approved by the FDA as an adjunct to diet in patients with high triglycerides. Similarly,
CLA has achieved the Generally Recognized As Safe (GRAS) status by the FDA for its use
in certain foods and beverages (11).
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We and others have shown that CLA profoundly reduces body fat mass and is popularly
used as a weight loss management strategy (5,12). We have also reported that CLA is antiosteoclastogenic and is able to prevent age-associated bone loss in mice (13). However,
CLA has been shown to exhibit some adverse effects (14) including reduction in insulin
sensitivity in subjects with type 2 diabetes (15) and augmentation of the pre-existing insulin
resistance (16,17). Additionally, long-term studies in rodents have demonstrated a
lipodystrophic effect of CLA (18) associated with decreases plasma adiponectin and leptin
levels and increased insulin resistance (19). There are paradoxical findings that CLA causes
liver enlargement (20) accompanied by increase in tissue lipid content in mice (14), whereas
in obese insulin-resistant rats, it reduced the hepatic steatosis, improved liver function, and
favorably modified lipid metabolism (21). On the other hand, FO has been shown to have
beneficial effects on glucose and lipid metabolism in rodent studies, improve insulin
sensitivity (22,23), reduce triglyceride (24) and to improve bone mineral density (BMD) in
ovariectomized mice (7). Thus, although CLA supplementation reduces body fat and
osteoporotic bone loss, it is associated with hepatomegaly and insulin resistance, whereas
FO is known to reduce triglycerides (TGs), improve insulin sensitivity, and enhance BMD.
Therefore, we speculate that the combining CLA with FO could be an excellent strategy in
the management of fat mass reduction and osteoporotic bone loss, circumventing the CLAinduced hepatomegaly and insulin resistance. In the present study, aging C57Bl/6J mice
were fed American Institute of Nutrition (AIN) 93 diet, containing 10% corn oil (CO) as a
dietary fat source, which promotes osteoporosis and obesity (25), glucose intolerance and
insulin resistance thus representing a useful model for studying the early stages in the
development of obesity (25,26) and age-related bone loss (25,27). The combined
supplementation of CLA and FO showed reduced fat mass, reduced BM adiposity, improved
hind leg lean mass (HLLM), improved BMD, along with no hepatomegaly and insulin
resistance in C57Bl/6J aging mice.
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2. Research Design and Methods
2.1 Animals
Eleven month-old female C57Bl/6J mice, weighing 24-26 g were purchased from Jackson
Laboratories (Bar Harbor, Maine 04609 USA) and provided free access to water and
standard chow AIN93G, which is the growth diet recommended by AIN for acclimatization
for a period of one month. At twelve months, weight matched animals were divided into
four groups containing 10 in each. Subsequently, the animals were housed in a standard
controlled animal care facility in cages (5 mice/cage) and fed a diet containing CO, FO,
CLA and combination of CLA and FO ad libitum for 6 months. The animals were
maintained in temperature controlled room (22 -25°C, 45% humidity) on a 12:12-h darkJ Nutr Biochem. Author manuscript; available in PMC 2012 May 1.
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light cycle. NIH guidelines were strictly followed, and all the studies were approved by the
Institutional Laboratory Animal Care and Use Committee of the University of Texas Health
Science Center, San Antonio, TX. Body weight was measured weekly.
2.2 Diet preparation
The 4 different experimental diets (Table 1) were prepared using AIN93G, supplemented
with CO, FO, and CLA as follows,
a.

Corn oil (CO) diet: supplemented with 10% corn oil,

b. FO diet: Supplemented with 5% FO ((eicosapentaenoic acid (EPA)/
docosahexaenoic acid (DHA) =30/20)) with 5% CO,
c.

CLA diet: Supplemented with 0.5% Clarinol-80™ (containing 50:50 of cis 9 trans
11 CLA and trans 10 cis 12 CLA) in 9.5% CO (CLA),

d. CLA+FO diet: Supplemented with 0.5% CLA in 4.5%CO with 5% FO (CLA+FO).
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The Clarinol-80™ was supplied by Lipid Nutrition, Channahon, IL, USA. FO (EPA/
DHA=30/20) was obtained from Ocean Nutrition, Canada. The mice were provided with
fresh food everyday between 1.00-2.00 PM. Diets were prepared each week, purged with
nitrogen, and frozen in daily portions in sealed polyethylene bags to minimize the oxidation
of fatty acids. The composition of semi-purified diets is presented in Table 1.
2.3 Measurement of BMD, total body fat mass and hind leg lean mass measured by DXA
Region specific BMD, total body fat mass (BFM), and hind leg lean mass (HLLM) were
measured by DXA before start of the AIN93 diet and after 6 months on the diets, and data
were analyzed using Lunar PIXImus mouse software (7,25). Prior to scanning, mice were
anesthetized with an intramuscular injection of 0.1 mL/100 g body weight of mouse cocktail
containing Ketamine/Xylazine/PBS (3:2:5, by vol). Upon completion of scanning, BMD
was determined in the following bone areas using the PIXImus software, version 2.1: distal
femoral metaphysis (DFM) (knee joint) to include cancellous (trabecular) bone, proximal
tibial metaphysis (PTM) and femoral diaphysis (FD). Intra-scan coefficients of variation
were 0.79%, 3.30% and 1.35% for DFM, PTM, and FD respectively; interscan coefficients
of variation were 5.47%, 3.86%, and 5.12% for DFM, PTM and FD respectively. The
coefficients of variation are in agreement with studies examining the precision and accuracy
of the PIXImus densitometer (28).
2.4 Intravenous glucose tolerance test (IVGTT)
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IVGTT was performed after 20 weeks using 6 mice from each dietary group. For the
IVGTT, 6 h-fasting mice were anesthetized with an intramuscular injection of 0.1 ml/100 g
body weight of mouse cocktail containing Ketamine/Xylazine/PBS (3:2:5, by vol). Blood
sample was drawn from the retrobulbar, intraorbital, capillary plexus followed by
intravenous injection of D-glucose (1 g/kg) into the tail vein (volume load 10 μl/g). Blood
samples were again drawn 5, 10, 20, 50, and 75 min after the glucose injection. After
immediate centrifugation at 4°C, serum was collected and stored at −80°C.
2.5 Blood and tissue collection for biochemical and histological analysis
After 6 months on the experimental diet, the animals were sacrificed. One week prior to
sacrifice, mice were fasted for 6-8 hrs, blood samples were taken from the intraorbital,
retrobulbar plexus from anesthetized mice to measure fasting glucose, insulin and nonesterified fatty acid in serum (NEFA). At the end of 6 months, the mice were anaesthetized
and blood was obtained by intraorbital capillary plexus. Serum was collected and stored at
−80°C. Liver, gastrocnemius and quadriceps muscles were collected, weighed and frozen in
J Nutr Biochem. Author manuscript; available in PMC 2012 May 1.
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liquid nitrogen and stored in −80°C. Spleen, tibia and femur were processed for subsequent
splenocyte culture and BM culture respectively. Right side of complete hind leg was fixed in
4% formalin and processed for Oil Red O staining to measure BM adiposity after dietary
intervention.
2.6 Measurement of serum metabolites
Serum glucose (QuantiChrom, Hayward, CA), triglycerides (TGs) (Cayman Chemical
Company, MI), NEFA (Wako Pure Industries Ltd, Japan), catalase and malondialdehyde
(MDA), (Cell Biolabs Inc., CA) were analyzed spectrophotometrically using Colorimetric
Assay Kits following manufacturers’ protocol. Insulin was analyzed using a rat/mouse Ultra
sensitive rat insulin ELISA kit (Crystal Chem Inc. Research, Downers Grove, IL).
Adiponectin and leptin were analyzed by using ELISA kits (R&D systems Inc.,
Minneapolis, MN) following manufacturer’s protocol.
2.7 Splenocytes preparation and culture
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Spleen was aseptically removed and placed in 5 ml of RPMI 1640 medium (Gibco, Grand
Island, NY) supplemented with 25 mmol/L HEPES, 2 mmol/L glutamine, 100,000 U/L
penicillin and 100 mg/L streptomycin (Gibco, Grand Island, NY). Single-cell suspensions
were made by teasing spleens between frosted ends of two sterile glass slides. After a 5-min
centrifugation at 1000 rpm to separate cells from debris, the cells were washed twice in
RPMI medium. Splenic lymphocytes were isolated by layering over Histopaque (Sigma, St.
Louis, MO), centrifuging at 1000 rpm for 15 min at 22°C followed by washing twice in
RPMI 1640 complete medium. Cells were counted, and viability was determined by trypan
blue exclusion method (25).
2.8 Isolation of whole BM cells and culture
Whole BM cells were aseptically isolated as described (25). In brief, cells were counted and
viability was determined by trypan blue exclusion method. Cells (10 × 106/well) were plated
in 12 well plates and bacterial LPS was added at the concentration of 5.0 μg/ml for 24 h at
37°C in a humidified atmosphere of air/CO2 95:5 (mol %). After 24 h, cells and culture
medium were collected together and centrifuged at 2000 rpm for 5 min. The pellets were
stored at −80°C for gene expression assays and supernatants were analyzed for TNF-α and
IL-6. BM cells cytosolic extract were used to measure the levels of MDA, catalase and
SOD.
2.9 Hematoxylin and eosin (H&E) staining of liver tissue
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After animal sacrifice, liver tissues were excised and fixed in 10% formalin for 24 hrs at
room temperature (RT). Tissue was then embedded in paraffin following conventional
methods. 5 μm sections were made and stained with H&E staining procedure for subsequent
histological analysis.
2.10 Cathepsin K (ctsk) and PPARγ gene expression in BM cells by real time RT-PCR
mRNA expression for genes encoding ctsk and PPARγ were measured using real time RTPCR. Frozen bacterial LPS-stimulated BM cells were vortexed in lysis buffer and RNA was
isolated using RNeasy Mini Kit following the manufacturer’s instructions (Qiagen,
Valencia, CA). Total RNA concentration was assessed in NanoDrop™ 1000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). Real time RT-PCR was
carried out using TaqMan® RNA-to-CT 1-step kit (Applied Biosystems, Foster City, CA) in
an ABI Prism 7900HT Sequence Detection System (Applied Biosystems) using fluorescent
TaqMan methodology. Real time quantitative PCR was performed for each of the following
genes, using ready-to-use primer and probe sets predeveloped by Applied Biosystems
J Nutr Biochem. Author manuscript; available in PMC 2012 May 1.
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(TaqMan Gene Expression Assays) were used to quantify ctsk (Ctsk, Mm00484036_m1),
peroxisome proliferators-activated receptor (PPARγ) (pparγ, Mm01184321_m1) and
Glyceraldehyde-3-phosphate dehydrogenase (Gapdh, Mm99999915_g1) as an endogenous
control. mRNA Ct values for these genes were normalized to the house-keeping gene
GAPDH and expressed as relative increase or decrease compared to the CO group.
2.11 Histological evaluation of femur head for bone adiposity by Oil Red O staining
Formalin fixed hind leg bones were placed in saturated solution of linoleic acid in ethylene
glycol (500ml of 70% ethylene glycol and 5g of linoleic acid were mixed for one hr at RT,
allowed to stand for several hrs at RT in a separating funnel, and the bottom layer drawn off)
for 3 days at 56°C. Bones were then sequentially rinsed for 8 hrs each in several changes of
70% ethanol at RT followed by with several changes of water. The bones were decalcified
in 2% chromic acid for 40 hrs at 4°C followed by rinsing with water for 8 hrs and incubation
with 5% aqueous sodium bicarbonate for 24 hrs at RT. The bones were finally rinsed with
several changes of water for 24-72 hrs at RT. Bones were then placed in 70% ethanol and
processed, embedded in paraffin and stained with 0.5% Oil Red O in isopropanol (w/v) for
10 min. Lipid vacuole area were assessed using a light microscope with a digitalized camera
and a Metaview image analysis system (Olympus America Inc, PA). The area of lipid
vacuoles was calculated from six different fields.
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2.12 Measurement of malondialdehyde (MDA) levels, catalase (CAT) and superoxide
dismutase (SOD) activity in BM cells
After 24 hrs BM cells treated with bacterial LPS were used to prepare cytosolic extracts
using a Nuclear Extract Kit from Active Motive (Carlsbad, CA), following manufacturer’s
protocol. Fifty micrograms of cytosolic extracts were used to determine MDA levels, CAT
and SOD activities using commercially available kits.
2.13 Cytokines measurement in serum, conditioned medium of cultured splenocytes and
BM cells
Isolated BM cells and splenocytes (10×106 cells/well) were plated in 6-well plates and
incubated with 5.0 μg/ml of bacterial lipopolysaccharide (LPS) for 24 h at 37°C in a
humidified atmosphere of air/CO2 95:5 (mol%). After 24 h, the culture medium was
collected and analyzed for TNF-α and IL-6 by Ready-set-go ELISA kits (eBioscience, Inc.
San Diego, CA) following manufacturer’s protocol.
2.14 Statistical analysis
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Data are presented as mean values ± SEM. Differences among the groups (CO, FO, CLA
and CLA+FO) were tested by one-way analysis of variance (ANOVA) followed by
Newman-Keuls multiple comparison post-hoc test. A p value P≤0.05 was considered
statistically significant. The analyses were performed using Graphpad prism for Windows
(La Jolla, CA, USA).

3. Results
3.1 Effect of CLA+FO on body weights and CLA-induced liver enlargement
The initial body weights for 12 months old C57Bl/6J mice in CO, FO, CLA and CLA+FO
groups were 25.59±0.60, 24.84±0.79, 25.17±0.26 and 24.50±0.61 g respectively. Chronic
six months feeding of CLA and CLA+FO caused a significant reduction (P<0.05) in body
weight gain when compared to CO fed mice (Figure 1A). The CLA-fed mice showed a 6%
weight gain compared to 28% in CO-fed mice, the difference between the two being very
highly significant (P<0.01). Similarly, CLA+FO fed group showed lowered body weight

J Nutr Biochem. Author manuscript; available in PMC 2012 May 1.
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gain (9%) compared to CO fed group (28%). However, no significant change in body weight
gain (27%) was observed in mice fed FO alone. The CLA fed mice showed significant
increase in liver weight compared to CO, FO and CLA+FO fed mice. The liver weight in
CLA fed mice was 2.17±0.10 g, which was significantly higher (P<0.001) than that of CO,
FO, and CLA+FO fed mice in which livers weighed 1.43±0.06, 1.12±0.1 and 1.38±0.09 g
respectively (Figure 1B). The data of the present study confirmed that CLA-induced liver
enlargement in C57Bl/6J aging mice is prevented by supplementation with FO whereas the
FO-induced body weight gain is thwarted by CLA.
3.2 Histological changes in CLA-induced fatty liver by CLA+FO
Histological sections of liver tissue from CO and CLA-fed mice showed predominantly
large lipid-filled vacuoles (macrovesicular steatosis) Figure 1C. Liver sections from FO and
CLA+FO group revealed a reduction of lipid accumulation, in the form of lipid droplets, or
even small lipid droplets (microvesicular steatosis). The histomorphometric analysis using
microscopy of lipid vacuole area revealed visibly significant differences between the
different groups where the lipid vacuole areas in CO, CLA, FO and CLA+FO fed mice
livers were 5.49±0.4 μm2, 24.59±0.6 μm2, 0.31±0.1 μm2 and 0.96±0.1 μm2 respectively
(Figure 1C). The lipid areas were significantly (P<0.001) higher and larger in CO and CLA
fed mice compared to that of FO and CLA+FO fed mice, confirming that FO prevented
CLA-induced liver steostasis.
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3.3 Improvement of insulin resistance by CLA+FO
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The higher circulating levels of NEFA in CO fed mice represents insulin resistance, which is
strongly associated with obesity, and one of the mechanism may be the generation of
metabolic messengers, such as free fatty acids, by adipose tissue that inhibit insulin action
on muscle (29). The fasting serum glucose concentration increased significantly (P<0.05) in
CO and CLA fed mice compared to FO and CLA+FO fed mice (Figure 2A). Contrarily,
fasting serum insulin concentration also increased in mice treated with CLA for six months,
demonstrating hyperinsulinemia which is comparable to CO. However, in CLA+FO fed
mice, increased insulin level was associated with reduction in blood glucose concentration
suggesting its ability to control hyperglycemia unlike CLA. The serum TGs were
significantly (P<0.05) decreased in FO, CLA and CLA+FO compared to CO fed mice
(Table 2). Surprisingly, fatty liver was observed in CLA fed mice, despite a reduction in
TGs levels compared to CO fed mice. Finally, CLA+FO decreased TG levels, improved
insulin levels and reduced glucose levels compared to CO as well as CLA. Fasting serum
NEFA was also found to be significantly (P<0.05) decreased in FO and CLA+FO fed mice
compared to CO group (Table 2). Furthermore, adiponectin levels (Table 2) were
significantly (P<0.03) increased in CLA+FO fed mice compared to CO fed mice in contrast
to leptin levels which were reduced significantly (P<0.05) in CLA+FO than CO. These
results suggest an affirmative role of CLA+FO in improving CLA-induced insulin resistance
and dysmetabolism in high fat fed C57Bl/6J aging mice.
3.4 Intravenous glucose tolerance test (IVGTT)
The IVGTT was performed at 20 weeks of feeding of experimental diet. At 5, 10 and 20
minutes after IV injection of glucose, the CLA+FO fed mice eliminated glucose faster than
CO and CLA fed mice. In contrast, the CO and CLA fed mice showed lesser elimination of
glucose, at both 50 and 75 minute time points (Figure 3A), although a higher concentration
of insulin was observed at these points. Thus, taken together, the basal levels of glucose and
insulin, as a result of glucose challenge, demonstrated that CLA and CO treated mice
display a more extensive impairment of β-cell function and, consequently, an exaggerated
insulin resistance compared with CLA+FO fed mice. The 5-min insulin response to
intravenous glucose challenge was increased rapidly to 1.63±0.04 (ng/ml) in CO and
J Nutr Biochem. Author manuscript; available in PMC 2012 May 1.
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1.78±0.35 (ng/ml) in CLA fed mice, however, it was apparently insufficient to maintain
normal glucose tolerance. A more pronounced and significant (P<0.05) increase in insulin
secretion was observed by glucose challenge in CLA fed mice demonstrating
hyperinsulinemia Figure 3B, unlike in CLA+FO fed mice.
3.5 CLA+FO increases BMD in femur and tibia regions measured by DXA
Baseline BMD of different bone regions measured prior to the start of the experimental diet
showed no differences among the groups. To examine the effect of CLA+FO on ageassociated bone loss, we measured the BMD after feeding the experimental diet for 6
months, using DXA. The results are expressed as % difference, as shown in Figure 4A, B
and C. The BMD in the distal end of the femoral metaphysis (DFM), proximal end of the
tibial metaphysis (PTM), and the femoral diaphysis (FD) regions of the FO, CLA and CLA
+FO fed mice was significantly higher (P<0.01) than that of CO fed mice. These findings
indicate that 12 months old mice, when placed on CO enriched diet for 6 months, resulted in
bone loss (25), which was restored by FO, CLA and CLA+FO dietary intervention.
3.6 Reduction of BM adiposity by CLA+FO
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Oil Red O staining of femoral head from 18 months old mice fed an experimental diet for 6
months, revealed a significant (P<0.01) increase in vacuole area of adipocytes (Figure 4D),
in CO (1.22±0.7 μm2) and FO (1.4±0.6 μm2) fed mice when compared to CLA (0.09± 0.03
μm2) and CLA+FO (0.18±0.04 μm2) fed mice. Bone forming osteoblasts and fat forming
adipocytes are both derived from mesenchymal stem cells (MSCs) (30), which are found in
many tissues and are abundant in the BM stroma (31). Of note, the fat cell size was also
reduced in FO, CLA and CL+FO, which is important determinant of age-related adiposity
(32). Reduction of BM adiposity in the femur head section revealed the positive role of
CLA, CLA+FO and FO fed mice in the prevention of age-associated bone loss (Figure 4E).
3.7 CLA+FO decreases total body fat mass (BFM) and increases HLLM measured by DXA
Total BFM was decreased (Figure 5A) and HLLM was significantly (P<0.05) increased
(Figure 5B) in CLA and CLA+FO fed mice compared to CO fed mice. Furthermore, we
noted the skeletal muscle wet weight of quadriceps and gastrocnemius muscles were
moderately increased (not significant, data not shown) in CLA and CLA+FO fed mice. The
increased weight of the skeletal muscle, showed by DXA analysis demonstrated a significant
(P<0.05) increase in HLLM in CLA (9%) and CLA+FO (10%) fed mice compared to that in
CO (−10%) fed mice (Figure 5B).
3.8 Gene expression by LPS-stimulated BM cells
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Quantitative real time RT-PCR further demonstrated that, bacterial LPS-stimulated mRNA
expression of ctsk was significantly decreased (P<0.05) in BM from FO, CLA and CLA+FO
groups as compared to that in CO group, demonstrating that FO, CLA or their combination
decrease osteoclastogenic bone resorption, thus improving BMD (Figure 6A). Attempts
were made to determine the RUNX2 mRNA expression, however, the levels were not
detectable in BM cells (Data not shown). Additionally, the PPARγ expression was
significantly (P<0.05) decreased in FO, CLA and CLA+FO fed mice compared to that in CO
fed mice (Figure 6B). An additive inhibitory effect on PPARγ expression was observed in
CLA+FO fed mice. The inhibitory effects of CLA+FO on ctsk and PPARγ in BM cells
confirmed their possible protective effect against bone resorption in aging mice.
3.9 CLA+FO decreases MDA levels and increases catalase activity in BM cells
The CO diet fed mice showed a significant (P<0.02) increase in MDA levels compared to
FO, CLA and CLA+FO fed mice. In contrast, anti-oxidant enzyme CAT activity was
J Nutr Biochem. Author manuscript; available in PMC 2012 May 1.
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significantly (P<0.001) increased in FO, CLA and CLA+FO fed mice groups when
compared to CO fed mice (Figure 6C and D). Even though, there was increase in superoxide
dismutase activity in FO, CLA and CLA+FO fed mice, it was not significantly different
from that in CO fed mice. It is established that osteoporotic women have significantly
reduced antioxidant enzyme activity and increased lipid peroxidation end-product, like
MDA (33). Previous reports have shown that reactive oxygen species such as superoxide
anion are involved in the pathogenesis of bone loss by stimulating osteoclast differentiation
and bone resorption (34). These results indicated that a combination of CLA+FO may
suppress osteoclastic bone resorption in mice by inhibiting the reactive free radicals or lipid
peroxidation.
3.10 Effect of CLA+FO on LPS-stimulated pro-inflammatory cytokines production by
splenocytes and BM cells
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We observed protective effect of CLA+FO against age-associated BMD-loss in mice,
through the regulation of bone-resorbing, inflammatory cytokines expression. Proinflammatory cytokines such as, IL-6 and TNF-α, are key regulators of osteoclastogenic
activity and have been shown to increase bone resorption with age in humans (35).
Interestingly, we found significant (P<0.04) decrease in IL-6 and TNF-α production in LPStreated splenocytes (Figure 7 A and B) and BM cells (Figure 7 C and D) of CLA+FO fed
mice compared to that in CO fed mice. These results indicate that the reduction of proinflammatory cytokines by BM and splenocytes may prevent age-associated bone loss
indirectly by inhibiting bone resorbing osteoclastogenesis.

4. Discussion
Given the escalating prevalence of overweight population and osteoporosis worldwide, it
would be advantageous to identify potential therapeutic nutrients/functional foods capable of
decreasing fat mass as well as preventing bone loss. CLA is widely used in weight loss
management and to reduce fat mass (12,36), which is the principal etiological factor of the
metabolic syndrome like insulin resistance and type 2 diabetes. CLA has been known to
improve BMD in animals (13). However, supplementation with CLA or its t10,c12 isomer is
associated with induction of insulin resistance and transmigration of lipids to liver resulting
in hepatic steostasis (14). In this investigation, attempts have been made to reduce CLAinduced liver hypertrophy and insulin resistance by incorporating FO in the CLA
supplemented diet, as FO is also known to reduce TGs and improve insulin sensitivity, as
well as BMD. Additionally, we have ascertained the novel use of CLA with FO in
maintaining BMD and muscle mass in high fat diet fed C57Bl/6J aging mice.
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In this dietary intervention study, we demonstrated that combination of CLA and FO
alleviates CLA-induced insulin resistance and hepatic steatosis in C57Bl/6J aging mice.
Importantly, in addition to that, it also helps to prevent age-associated bone loss, decrease fat
mass and increase hind leg lean mass. These beneficial effects on age-associated bone loss
were associated with increased BMD, decreased BM adiposity and down-regulation of
genes involved in osteoclastogenesis, as well as osteotropic factors, such as TNF-α and IL-6.
Furthermore, CLA+FO induced the production of potent anti-inflammatory, antisteatotic,
insulin-sensitizing adipokine, e. g. adiponectin.
Non-Alcoholic Fatty Liver Disease (NAFLD) is distinctive among liver diseases, because its
etiology is closely related to the metabolic syndrome (37), observed similarly in CLA
(14,38). Much of the increased prevalence of NAFLD is driven by weight gain particularly
in aging (37) in which visceral fat is the most important factor for the development of
hepatic steatosis (39) in obese people. Interestingly, CLA reduces visceral fat, but develops
insulin resistance, which is commonly observed in CLA fed mice (14,40), and humans
J Nutr Biochem. Author manuscript; available in PMC 2012 May 1.
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(16,41). Indeed, it has been reported that in the absence of obesity, even in patients with
total lipodistrophy, insulin resistance leads to hepatic steatosis (42,43). Although the
mechanisms underlying the association of insulin resistance and hepatic steatosis remain
unclear, altered insulin sensitivity has been shown to increase hepatic de novo lipogenesis
and to induce lipolysis of adipocyte TGs and flux of free fatty acids to the liver (44). Our
results showed a significant improvement in the glucose tolerance test curves in high fat diet
fed C57B6J aging mice supplemented with CLA+FO, presumably by decreasing TGs levels,
and by inducing glucose uptake and insulin-signaling components which in turn contributes
to the antisteatotic actions of FO+CLA. It is established by a number of investigators that
FO supplementation increases adiponetin levels (45,46) and up-regulates PPARα, a key gene
involved in the control of hepatic peroxisomal β-oxidation of fatty acids (47). DHA, a strong
PPARγ activator, arouses further interest in developing FO derivatives as a potent antidiabetic drug, without producing undesirable effects, such as obesity and hepatotoxicity
(48).
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It was previously believed that obesity and osteoporosis were two unrelated diseases. But
recent studies have shown that both diseases share several common genetic and
environmental factors (2,25). The common precursor mesenchymal stem cells (MSCs) (30)
that leads to the differentiation of both adipocytes and osteoblasts, as well the secretion of
adipocyte-derived hormones that affect bone metabolism, may partially explain these
associations. Recently Naveiras et al suggested that adipocytes in BM alter the
microenvironment and may have negative consequences for the skeleton. Fat overload
would replace functional hematopoietic and/or osteogenic cells from the BM cavity (49).
Reduction of adipose tissue in femur head bone sections suggests the possible role of CLA
+FO in osteoblast formation. Number of studies on adipocyte function has revealed that
adipose tissue is not just an inert organ for energy storage, but acts as an endocrine organ
(50)capable of expression and secretion of a variety of biologically active molecules, such as
estrogen, resistin, leptin, adiponectin, IL-6, TNF-α etc,) (50). These molecules affect human
energy homeostasis and also may be involved in bone metabolism, which may contribute to
the complex relationship between fat mass and bone. Body fat mass, a component of body
weight, is one of the most important indices of obesity, and a substantial body of evidence
indicates that fat mass may have beneficial effects on bone (2). However, in our studies CO
fed obese mice exhibited reduced BMD compared to FO, CLA and FO+CLA fed mice.
Based on our current state of knowledge, it is unclear whether fat has beneficial effects on
bone. We anticipate that this will be an active and fruitful focus of research in the coming
years.
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Previous work in our laboratory has demonstrated a reduction in ovariectomy-induced BMD
loss in mice by dietary FO, accompanied by decreased osteoclastogenesis (7), and also
revealed this molecular mechanism by using a fat-1 transgenic mouse model which has the
inherent ability to produce n-3 fatty acids from n-6 fatty acids (51). Importantly, our group
also showed the beneficial effect of FO on bone mass during aging, by modulating bone
formation and bone resorption factors (52). Furthermore, feeding CLA diet in middle-age
mice suggests that the loss of bone and muscle may be prevented by modulating the markers
of inflammation and osteoclastogenic factors (13). In this current study, we revealed that
ctsk, which is abundant in osteoclast, plays a vital role in bone resorption (53), and was
down-regulated in CLA+FO fed mice, demonstrating that prevention of age-associated bone
loss might be related to bone resorption. It is established that oxidative stress is negatively
associated with bone loss (54). Decreased oxidative stress, as measured by MDA levels and
increased CAT activity explains partly the mechanism of bone loss prevention by CLA+FO
supplementation.
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The results of the current study strongly support the concept that an increased intake of FO
would contribute to the prevention of age-associated bone loss and to the prevention of
CLA-induced insulin resistance and metabolic liver disease (55), similar to the improved
outcomes reported in cardiovascular disease, arthritis, cystic fibrosis, IgA nephropathy,
diabetes, ulcerative colitis, Crohn’s disease, asthma, and sepsis (24). Our results are
consistent with previous investigations reporting that CLA-induced hepatomegaly can be
prevented using FO (56,57) and flaxseed oil (55). Additionally, our studies revealed that,
CLA+FO increases BMD by decreasing the BM adiposity in the femur bone; FO, in
combination with CLA, decreases the inflammation status by reducing the pro-inflammatory
cytokines (TNF-α, and IL-6) and eventually, reduction in oxidative stress which partially
explain the mechanism of bone loss prevention by CLA+FO.
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In summary, age-associated protection of bone loss by individual fatty acids such as CLA
(13), FO (52) and also combination of FO with CLA is associated with decreased total fat
mass in mice (57) in agreement with human studies (56) further confirming the benefits of
FO supplementation in CLA-induced liver hypertrophy and insulin resistance. Additionally,
CLA+FO significantly contributed to the prevention of BM adiposity and increased hind leg
lean mass in aging mice. In conclusion, this finding provides a strong and compelling
rationale for dietary supplementation of FO during clinical trial with CLA in obese, insulinresistant aging patients in order to prevent osteoporosis. Additional studies in higher species
and humans are still needed before the use of CLA+FO, as a dietary supplement to reduce
obesity and osteoporosis in humans.
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Figure 1.

Effect CO, FO, CLA and CLA+FO on body weight (A), liver weight (B) and liver histology
(C). 12 month old C57Bl/6J mice (n=10) were fed CO, FO, CLA and CLA+FO for 6
months. (C) Panels show hematoxylin and eosin (H&E)-stained liver sections from
representative mice (n = 6/group). White circular area represents lipid. Values represent total
lipid area (μm2) by histomorphometry. Images are x200 magnifications. Values with
different letters are significantly different by one way ANOVA followed by Newman-Keuls
multiple comparison post-hoc test (P<0.05).
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Figure 2.

Effect of CO, FO, CLA and CLA+FO on the fasting glucose (A) and Insulin (B). 12 month
old C57Bl/6J mice (n=10) were fed with CO, FO, CLA and CLA+FO for 6 months. Values
with different letters are significantly different by one way ANOVA followed by NewmanKeuls multiple comparison post-hoc test (P<0.05).
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Figure 3.

Plasma levels of glucose (A) and insulin (B) after intravenous glucose administration: 1g/kg
glucose was injected into the tail vein of mice fed with CO, FO, CLA and CLA+FO. The
IVGTT was performed 5 months after starting the diets. Data are means ± SEM from 6
independent experiments. Values with different letters are significantly different by one way
ANOVA followed by Newman-Keuls multiple comparison post-hoc test (P<0.05).
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Figure 4.

Effect of CO, FO, CLA and CLA+FO on BMD of (A) distal femoral metaphysis (DFM), (B)
proximal tibial metaphysis (PTM) and (C) femoral diaphysis (FD). Values represent
percentage of change in BMD from baseline value determined at the beginning of the
experiment. (D) Histomophometric evaluation of femoral adipocyte vacuole area (μm2). (E)
Representative photomicrographs of femoral head bone marrow adiposity – Femurs were
processed after dietary supplementation of CO, FO, CLA and CLA+FO and stained with Oil
Red O. Upper panel (4x, scale bar is 500 μm.) demonstrated reduced adiposity in CLA and
CLA+FO fed mice than CO and FO fed mice (n = 5/group). Lower panel (10x, scale bar is
200 μm.) showed reduced adipocyte cell area in CLA and CLA+FO fed mice than CO and
FO fed mice. 12 month old C57Bl/6J mice (n=10) were fed with CO, FO, CLA and CLA
+FO for 6 months. Values with different letters are significantly different by one way
ANOVA followed by Newman-Keuls multiple comparison post-hoc test (P<0.05).
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Figure 5.

Effect of CO, FO, CLA and CLA+FO on the total fat mass (A) and hind leg lean mass (B).
12 month old C57Bl/6 mice (n=10) were fed with CO, FO, CLA and CLA+FO for 6
months. Values with different letters are significantly different by one way ANOVA
followed by Newman-Keuls multiple comparison post-hoc test (P<0.05).
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Figure 6.

CLA and CLA+FO down-regulate the expression of cathepsin K (A) and PPARγ (B).
Expression of osteoclast specific gene cathepsin K and adipocyte specific PPARγ in C57Bl/
6J (n=6) aging mice was determined by quantitative real-time RT-PCR in LPS-stimulated
bone marrow cells from mice fed either fat diet CO as a control or diet enriched with FO,
CLA and CLA+FO for 6 months. MDA (C) and catalase (D) activity in bone marrow cells
after dietary supplementation of CO, FO, CLA and CLA+FO in aging mice. 12 month old
C57Bl/6J (n=6) mice were fed with CO, FO, CLA and CLA+FO for 6 months. Results are
expressed as means ± SEM; Values with different letters are significantly different by one
way ANOVA followed by Newman-Keuls multiple comparison post-hoc test (P<0.05).
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Figure 7.

Effect of CO, FO, CLA and CLA+FO on LPS-stimulated TNF-α and IL-6 secretion by
splenocytes (A and B) and bone marrow cells (C and D). 12 month old C57Bl/6J (n=6) mice
were fed with CO, FO, CLA and CLA+FO for 6 months and used for splenocytes and bone
marrow cells culture. Values with different letters are significantly different by one way
ANOVA followed by Newman-Keuls multiple comparison post-hoc test (P<0.05).
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Table 1

Composition of semi-purified experimental diets
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Ingredientsa

Percent

Casein

14.00

Corn starch

42.43

Dextronized corn starch

14.50

Sucrose

9.00

Cellulose

5.00

AIN-93 mineral mix

3.50

AIN-93 vitamin mix

1.00

l-cystine

0.18

Choline bitartrate

0.25

TBHQ

0.10

Vitamin E

0.04

COb, FOc, CLAd, FO+CLAe

10.00

a

NIH-PA Author Manuscript

All diet ingredients were purchased from MP Biomedicals (Irvine, CA). CLA from Lipid Nutrition, Channahon, IL, USA and Fish oil
((eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) =30/20)) from Ocean Nutrition, Canada.
b

Diets consisted of 10% CO or 5% CO with 5% FO or 0.5% CLA 9.5 in CO or 0.5 % CLA in 4.5% CO with 5% FO respectively.

c
Diets consisted of 10% CO or 5% CO with 5% FO or 0.5% CLA 9.5 in CO or 0.5 % CLA in 4.5% CO with 5% FO respectively.
d

Diets consisted of 10% CO or 5% CO with 5% FO or 0.5% CLA 9.5 in CO or 0.5 % CLA in 4.5% CO with 5% FO respectively.

e
Diets consisted of 10% CO or 5% CO with 5% FO or 0.5% CLA 9.5 in CO or 0.5 % CLA in 4.5% CO with 5% FO respectively.
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Table 2

Serum metabolites and cytokines in C57Bl/6J mice fed CO, FO, CLA and CLA+FO for six months.
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Serum metabolites
Parameter

CO

FO

CLA

CLA + FO

Triglycerides (mg/dl)

70.28±2.15a

40.66±2.42b

45.33±6.12b

41.21±3.05b

NEFA (mEq/L)

1.24±0.06a

0.81±0.06b

1.04±0.03a

0.88±0.03b

Serum hormones and adipocyte cytokines
Leptin (μg/ml)

7.41±0.63a

5.22±0.60a

3.38±0.22b

4.30±0.61b

Adiponectin (μg/ml)

1.93±0.06a

2.88±0.07b

1.16±0.04a

2.97±0.05b

TNF-α (pg/ml)

55.12±4.24a

42.23±2.26a

37.43±1.44b

37.22±2.12b

IL-6 (pg/ml)

120.9±6.30a

90.0±4.13a

93.12±7.12b

80.25±2.36b

Effect of diet containing CO, FO, CLA and CLA+FO on serum metabolites and cytokines in C57Bl/6J mice fed for six months. Data are means ±
SEM, (n=10 mice/group). Values with different letters significantly different by one way ANOVA followed by Newman-Keuls multiple
comparison post hoc test (P<0.05).
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